Scientists are testing a new kind of cancer vaccine that is specially designed for each individual patient, and early results suggest it may help people with one of the world’s deadliest brain cancers live longer.
The research was led by teams from Washington University School of Medicine together with researchers from other medical centers and a biotechnology company called Geneos Therapeutics.
The study was published in Nature Cancer.
The vaccine is being developed to treat glioblastoma, a fast-growing brain cancer that is extremely difficult to cure.
Glioblastoma spreads quickly through brain tissue and often returns even after surgery, radiation therapy, and chemotherapy.
Doctors have struggled to successfully treat this cancer for decades. Most patients survive only a limited time after diagnosis because the disease is so aggressive.
One major problem is that glioblastoma can hide from the immune system. Normally, immune cells patrol the body looking for dangerous invaders or abnormal cells. Cancer cells, however, sometimes develop ways to avoid being recognized.
Glioblastoma is especially good at hiding. Researchers often describe it as a “cold” tumor because it creates an environment that weakens immune activity around it. This makes it very hard for the body to launch a strong defense against the cancer.
Scientists hoped the new vaccine could change that.
Unlike traditional vaccines that are made for large populations, this treatment is built separately for each patient using information taken directly from the patient’s own tumor.
After surgeons removed part of the tumor, researchers studied the cancer cells carefully to identify unusual proteins called neoantigens. These proteins exist only on the patient’s cancer cells and not on healthy tissue.
Using advanced computer analysis, scientists selected dozens of these unique proteins and created a DNA-based vaccine that trains the immune system to recognize them.
The vaccine is called GNOS-PV01.
Researchers designed it to target as many as 40 tumor proteins at once, which is more than previous cancer vaccines had attempted. They hoped this broad attack would make it harder for the cancer to escape.
Cancer cells can evolve quickly. If a treatment targets only one protein, the tumor may survive by changing or removing that target. By aiming at many proteins at the same time, scientists believe the immune system may have a better chance of finding and destroying cancer cells.
The trial included nine adults with newly diagnosed glioblastoma. All were treated at Siteman Cancer Center.
Once each patient recovered from surgery and radiation therapy, researchers began giving vaccine injections. Treatments started around 10 weeks after surgery. Patients first received injections every three weeks and later continued treatment every nine weeks.
The vaccine appeared to activate the immune system in almost every patient. Researchers observed stronger immune-cell activity in all participants except one patient who was taking immune-suppressing steroids.
The survival results also appeared promising compared with what doctors usually expect from glioblastoma.
One-third of the patients experienced no cancer progression for at least six months after surgery. About two-thirds survived for at least one year, and two-thirds were still alive after two years. Normally, survival rates for glioblastoma are much lower.
One patient remains alive and free from cancer recurrence almost five years after diagnosis, which researchers say is highly unusual for this disease.
Scientists believe one reason the vaccine may work is because it not only helps immune cells recognize cancer proteins but may also change the tumor environment itself. The vaccine appears to help transform “cold” tumors into “hot” tumors that are easier for the immune system to attack.
Researchers say this dual effect could be especially important for difficult cancers like glioblastoma.
Another encouraging finding was safety. The study reported no serious side effects related to the vaccine. This is important because some cancer immunotherapies can cause severe immune reactions.
Still, researchers caution that the study is very small and remains in the early stages. Phase 1 trials mainly test safety and immune response rather than proving whether a treatment truly improves survival.
Because only nine patients participated, the results cannot yet prove that the vaccine works for most people with glioblastoma. Larger clinical trials involving many more patients will be needed.
Researchers also plan to study whether combining the vaccine with other therapies could improve results further. Some scientists believe pairing personalized vaccines with other immunotherapy drugs may create even stronger immune responses.
The study reflects a growing shift in cancer research toward personalized medicine. Instead of treating every patient with identical therapies, scientists are increasingly designing treatments based on the unique genetic features of each person’s cancer.
This approach may become especially important for cancers like glioblastoma, where standard treatments have produced only limited improvements over many years.
The findings also show how advances in genetics, DNA technology, and computer analysis are helping researchers create highly customized treatments that would have been impossible in the past.
Even though many questions remain, the study provides hope in an area of medicine where progress has been difficult. Glioblastoma remains one of the most challenging cancers to treat, and patients urgently need better options.
The research suggests that personalized DNA vaccines may eventually become an important new strategy for helping the immune system recognize and attack deadly brain tumors.
While more research is necessary before the treatment becomes widely available, the early findings are encouraging and may represent an important step toward more effective brain cancer therapies in the future.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
Source: Washington University School of Medicine.
